20 Years of Trust in Saving Nephrons
Evidence based Nephroprotective Nutraceutical to slow the progression of CKD
Nefrosave & Nefrosave Forte are the patented products of Fourrts
Nefrosave Patent No. IN300350
Nefrosave Forte Patent No. IN339847
Nefrosave Forte Patent No. IN339847
Nefrosave is the No.1 Anti-oxidant brand prescribed by Nephrologists in India*
Fourrts Awareness Initiative
Statewise Incidence of Microalbuminuria
First Time in India
- Conducted over 6000 Micral Camps
- Screened over 72000 Patients
Microalbuminuria
Prevalence in India
Int. J. Adv. Med. 2019
Prevalence of nephropathy detected through
microalbuminuria in type 2 DM was 44.7%
Prevalence of nephropathy detected through
microalbuminuria in type 2 DM was 44.7%
Int. J. Assoc. Physicians India. 2018
Prevalence of microalbuminuria in essential hypertension
was 47%
Prevalence of microalbuminuria in essential hypertension
was 47%
“As physicians, we take a solemn oath to serve our patients and community, to do no harm and always put our patients first. At Fourrts, we use the same guiding principles to manufacture and market quality pharmaceutical formulations to serve patients in India and across the globe. We understand the emotional and economic ramifications of chronic disease and seek to be your partner in providing the best care for our patients”
Dr. Gayatri Veeramani Jayaraman M.D., MHA (USA)
American Board Certified Physician & Nephrologist (ABIM) Director of Marketing & International Business – Fourrts
